Call for entries to Rainer Rudolph Foundation prizes

Closing date is 31 March

Young researchers who have completed an outstanding final thesis in the fields of protein biochemistry and biotechnology have another month to apply for a €1,000 Rainer Rudolph Foundation prize. Applications should be submitted to the Foundation in Germany by 31 March.

Friends, companions, former colleagues and staff of the late Professor Dr Rainer Rudolph established The Rainer Rudolph Foundation in 2011 to honour his scientific work. Prior to his death in 2009, Professor Rudolph was among the world’s leading protein biochemists as well as the co-founder of Scil Proteins, the company which now sponsors The Rainer Rudolph Foundation.


Dr Ulrike Fiedler, chief executive of the Foundation and Scil Proteins, said: ‘During his work, Professor Rudolph placed particular emphasis on linking scientific research with industrial applications and consequently, the foundation of Scil Proteins was a logical step for him. Through the years, we came to know and appreciate Professor Rudolph as a highly respected scientist and competent industrial partner. The Rainer Rudolph prizes have been established to encourage upcoming generations of scientists to excel in their work and therefore, I hope many young researchers in the fields of protein biochemistry and biotechnology will apply.’

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia

AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical

Boehringer Ingelheim adds antibody-based cancer drug from AimedBio to its portfolio

The two have signed a licence agreement, which will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with the new asset expected to enter first-in-human studies next year
Subscribe now